Physicians Hall Front

Data Supports Interaction of Pretreatment Immune Inflammatory State of Patient Outcomes following Radiotherapy in High Risk Prostate Cancer Trial

SAN ANTONIO, TX – Data from a validation study of NRG-RTOG 0521 suggests that, while there is no association between an elevated level of C-reactive protein (CRP) and disease-free survival (DFS); higher levels of pretreatment interleukin 10 (IL-10) were linked to lower rates of DFS. These results were recently presented at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

The initial study, NRG-RTOG 0521 (Hall 2013), indicated that elevated CRP levels, a marker of inflammation, were directly associated with shorter biochemical failure-free survival after radiotherapy for patients with high risk prostate cancer. During this study, serum samples were collected from 202 participants and banked for future biomarker validation. Researchers measured multiple serum immuno-inflammatory cytokines in addition to CRP levels. The primary objective for the validation study was to determine the association between CRP levels and DFS from time of patient randomization and additional objectives included the correlation of cytokine levels with DFS and toxicity events due to radiotherapy.

William Hall Headshot

William A. Hall, MD
Lead Author

“Although CRP levels did not correlate with DFS, the association of higher baseline levels of IL-10 with poorer outcome supports the claim that there may be an interaction between host pretreatment immune inflammatory state and the outcomes for the patient following radiotherapy treatment. I believe that future investigation into anti-inflammatory medical intervention for patients with prostate cancer in association to radiotherapy would be worthwhile,” stated William A. Hall, MD, an Assistant Professor of Radiation Oncology at the Medical College of Wisconsin and lead author of this abstract.

Serum immune-inflammatory cytokines that were studied included: monocyte chemotactic protein-1 (MCP-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFN-γ), IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17A, IL-23, and tumor necrosis factor (TNFα). In addition to the association between IL-10 and DFS, IL-12 and IL-13 were also associated with grade 2 or higher cystitis, or inflammation of the bladder.

Supported by: CTEP and the National Cancer Institute grants U10CA180868, U10CA180822, UC1CA189867, U24CA196067, and U24CA180803. Grant 14-247-29-IRG from the American Cancer Society.

Citation: Hall WA, Karrison T, Rosenthal SA, Amin M, Gomella LG, Purdy J, Sartor AO, Michalski J, Garzotto M, Bergom C, Jani AB, Lawton CAF, Simko JP, Moore J, Gore E, Lee WR, Nguyen PL, Danielson B, Sandler HM, Feng FY. The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521. Abstract presented at the annual meeting of the American Society for Radiation Oncology (ASTRO). San Antonio, TX.

About NRG Oncology

NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network.

MCW Media Contacts

The media relations team at MCW is happy to assist in coordinating experts for interviews. Please reach out to us at:
(414) 955-8761
Contact us

Contact Location Lab Photo